Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Patients with central centrifugal cicatricial alopecia may have a higher risk of breast and colorectal cancer.

PRP may help treat female hair loss, but more research needed.

This study reported that adding the topical product CG210 to oral finasteride 1mg significantly increased hair diameter more than finasteride alone in male androgenetic alopecia patients already stabilized on finasteride treatment.

This study found that oral spironolactone 100 mg daily for 24 weeks improved terminal hair counts and diameters in premenopausal women with female pattern hair loss when used alongside minoxidil, despite a higher incidence of menstrual irregularities.

This study found that PRP may increase hair density in breast cancer survivors with EIA or pCIA, but improvements did not differ statistically between treated and untreated sides.

This study found that a combination of topical 5% minoxidil and 0.25% finasteride was more effective at improving hair density and satisfaction in men with androgenetic alopecia than either treatment alone over 24 weeks.

This article reviews alopecia areata treatments, noting varied outcomes, and reports no new clinical results.

In this phase I study, partial hair regrowth was observed in patients with alopecia universalis using topical JAK inhibitors, though more research is needed to confirm potential as a treatment alternative to clobetasol.

Trichoscopy is a helpful and quick method to diagnose hair loss without shaving.

Dutasteride can help treat hair loss in both men and women.

This study found that 0.75% adenosine lotion significantly improved hair growth and thickness in Japanese women with female pattern hair loss compared to a placebo.

This study introduced laser-assisted exosome delivery and observed early signs of clinical improvement in two patients, though causality cannot be inferred from these preliminary, uncontrolled cases.

This pilot study suggests that platelet-rich plasma may be a promising treatment for chronic telogen effluvium with good safety, and cost-effective preparation methods may be reliable alternatives to more expensive ones.

This pilot study reported significant improvement in hair restoration and patient satisfaction with the use of fractional carbon dioxide laser followed by platelet-rich plasma, showing greater hair density increases using higher laser pulse energy settings in individuals with androgenetic alopecia.

This study found that human umbilical cord-derived mesenchymal stromal cell-conditioned media was safe and positively affected hair regeneration in 86.6% of participants in a pilot study.

In this study, Xtressé™ gummies were found to be safe and well tolerated, showing potential improvement in hair density among women with non-scarring alopecia over four months, while partially benefiting those with scarring alopecia; larger trials are encouraged.

This study aimed to evaluate the effectiveness of a hair conditioner containing Serenoa serrulata extract and tocoferol applied 3-4 times per week for 90 days against androgenic alopecia.

This pilot study observed that topical sildenafil 1% significantly increased vellus and terminal hair counts in female pattern hair loss patients, but did not improve hair thickness, while topical minoxidil 5% increased terminal hair count and thickness, making it the preferred treatment option.

This study found that a dietary supplement improved hair strength and shine in participants with hair damage from breakage.

This study found that a targeted iron supplementation program prevented anemia and improved blood return rates among premenopausal female blood donors with iron deficiency.

This study found that treatment with human foreskin fibroblast conditioned medium improved both objective measures like hair density and subjective satisfaction in patients with androgenetic alopecia.

This study found that an exosome formulation with plant extracts significantly increased hair regrowth in men with male pattern alopecia compared to a placebo, without notable adverse effects.

This study found that a topical henna formulation may improve symptoms like itching, burning, and redness in patients with recessive dystrophic epidermolysis bullosa, but larger controlled studies are needed.

This randomized pilot study suggests that finasteride may benefit some men with category IIIA chronic pelvic pain syndrome, although it is not recommended as monotherapy unless benign prostatic hyperplasia is also present.

This study demonstrated that the Alopecia Areata Assessment Tool (ALTO) effectively identifies alopecia areata cases with high sensitivity and specificity in a dermatology clinic setting.